Dr Collinson joined Forward Ventures as a Partner in 2003. Previously he was Chairman, Chief Executive Officer and President of Aurora Biosciences Corporation (acquired by Vertex Pharmaceuticals for $600 million). Before Aurora, Dr. Collinson was Chief Executive Officer of privately held Andaris (acquired by Quadrant plc, now part of Elan Corporation plc).  He held senior management positions at GlaxoWellcome plc (now GlaxoSmithKline plc) and Baxter International, and was a consultant with The Boston Consulting Group.  Dr Collinson is a director of Essentialis, Oxagen and Tioga Pharmaceuticals. Where he also serves as the Chairman and Chief Executive Officer. Dr Collinson was previously a director of Afinium Pharmaceuticals (acquired by Debiopharm), Cabrellis Pharmaceuticals (acquired by Pharmion, now part of Celgene Corporation), Conforma Therapeutics Corporation (acquired by BiogenIdec), GeneOhm Sciences (acquired by Becton Dickinson), NovaCardia (acquired by Merck & Co), Proprius Pharmaceuticals (acquired by Cypress Bioscience) and Vertex Pharmaceuticals (2001-2011).   Dr Collinson was awarded an MBA from Harvard Business School and a PhD in Physical Chemistry from the University of Oxford.

Stuart Collinson, PHD MBA